UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, E9
Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
Other Events
Earnings Release
Announces Approval of YUPELRI® (revefenacin) by China’s NMPA
Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Shareholder votes
Q2
Q1
FY 2024
FY 2023
Q3
SC TO-I
Tender Offer Statement by Issuer
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Tender Offer Statement by Issuer
Correspondence